Search results

How to register as a stakeholder with NICE.

Find out more about the types of organisations that can register to be a stakeholder at NICE.

NICE transparency of spend

Home Freedom of information...

Outside interests of the NICE board

NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

Ask an expert from NICE International, part of the UK's National Institute for Health and Care Excellence, to speak at a healthcare event in your country

The Innovative Licensing and Access Pathway (ILAP) is a unique initiative which works with medicine developers early on to help get new medicines to patients faster.

Evidence-based recommendations on intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer. This involves delivering electron beam radiation directly to the tumour during surgery. The aim is to stop the cancer from coming back and spreading further.

Result type

HealthTech guidance

Published

6 June 2023

Evidence-based recommendations on extracorporeal carbon dioxide removal for acute respiratory failure. This involves taking blood out of the circulatory system and passing it across a synthetic membrane that allows some of the carbon dioxide in the blood to be removed. The blood is then returned to the circulatory system.

Result type

HealthTech guidance

Published

15 November 2023

Evidence-based recommendations on cryotherapy for chronic rhinitis. This involves destroying a nerve in the nose to reduce chronic rhinitis symptoms.

Result type

HealthTech guidance

Published

14 September 2023

Evidence-based recommendations on aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease in adults. This involves replacing the diseased part of the valve with some of the person’s own pericardium.

Result type

HealthTech guidance

Published

9 August 2023

Evidence-based recommendations on maximal cytoreductive surgery for advanced ovarian cancer. This involves removing all or almost all visible cancerous tissue. More tissue is removed than with standard surgery. The aim is to improve outcomes for people with advanced ovarian cancer.

Result type

HealthTech guidance

Published

5 April 2023

Evidence-based recommendations on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. This involves removing parts of the pancreas (islet cells) after the pancreas has been removed and inserting them into the liver to restart insulin production.

Result type

HealthTech guidance

Published

24 September 2008

Evidence-based recommendations on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. This involves removing cells called islet cells, which are responsible for the production of insulin, from human donors.

Result type

HealthTech guidance

Published

23 April 2008